<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00801606</url>
  </required_header>
  <id_info>
    <org_study_id>ICTBSG</org_study_id>
    <nct_id>NCT00801606</nct_id>
  </id_info>
  <brief_title>Micronutrient Supplementation in in Paediatric Pulmonary Tuberculosis</brief_title>
  <acronym>ICTBSG</acronym>
  <official_title>Micronutrient Supplementation in Conjunction With Standard Anti-Tuberculosis Therapy in Paediatric (6 Months-15 Years) New Pulmonary Tuberculosis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>All India Institute of Medical Sciences, New Delhi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Bergen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>All India Institute of Medical Sciences, New Delhi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A recent trial in adults has demonstrated that zinc (Zn) and other Multiminerals (MN)&#xD;
      combined, but neither of them alone, significantly increased weight gain during Tuberculosis&#xD;
      (TB) treatment. There was a substantially larger beneficial effect on survival amongst those&#xD;
      who received the combination of Zn and MN compared with those who received either Zn alone or&#xD;
      MN alone. These exciting preliminary findings require further confirmation, as the data on&#xD;
      mortality reduction was based on a post-hoc subgroup-analysis. Effects of MN and Zn&#xD;
      supplementation has not been assessed in children with TB. Studies are urgently needed to&#xD;
      evaluate the therapeutic potential of nutritional interventions on treatment outcome in&#xD;
      children with TB. Simple and inexpensive nutritional interventions may substantially impact&#xD;
      TB-related child morbidity and mortality in high-burden settings. The investigators thus,&#xD;
      propose a randomized, double blind, controlled trial that will measure the effect of&#xD;
      multi-vitamin/mineral supplementation on the efficacy of anti-TB treatment in newly diagnosed&#xD;
      childhood pulmonary TB patients in Delhi.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We plan to do a randomized controlled trial to study impact of multimineral supplement with&#xD;
      antituberculosis drugs in freshly diagnosed pulmonary tuberculosis in children. Plan to enrol&#xD;
      400 children at two sites in Delhi. The diagnosis and treatment of pulmonary tuberculosis&#xD;
      will be based on recommendations of Revised National Tuberculosis Control Program (RNTCP).&#xD;
      The outcome will be measured in form of weight gain and improvement in x ray film of chest.&#xD;
      The secondary outcome variables will be as follows:&#xD;
&#xD;
        1. Effect of micronutrient supplements at 2 and 6 months on anthropometric parameters by&#xD;
           comparing means of anthropometric parameters in different groups.&#xD;
&#xD;
        2. Improvement in radiological findings at 2 months: Comparing the proportion of children&#xD;
           showing clearance of X ray films at baseline and 6 months by two paediatricians&#xD;
           independently using same protocol.&#xD;
&#xD;
        3. Resolution of symptoms at 2 and 6 months: By comparing proportion of patients having&#xD;
           resolution of presenting symptoms (fever, cough, appetite improvement) as reported by&#xD;
           parents&#xD;
&#xD;
        4. Proportion of children requiring extension of intensive phase of therapy: Comparing&#xD;
           proportion of children in different groups requiring extension of intensive phase of&#xD;
           therapy at 2 months due to the treating physician's decision.&#xD;
&#xD;
        5. Interferon gamma responses to M. tuberculosis antigens ESAT6 and CF10 by quantiferon&#xD;
           assay at baseline, 2 months and 6 months of treatment&#xD;
&#xD;
        6. To study effect of zinc supplementation on ocular toxicity in children receiving&#xD;
           ethambutol by VER&#xD;
&#xD;
        7. To document drug resistance (S, I, R, E) patterns among children with culture confirmed&#xD;
           TB&#xD;
&#xD;
        8. To document genotypic strain diversity among children with culture confirmed TB, also&#xD;
           associations between strain type and disease severity and/or drug resistance&#xD;
&#xD;
        9. To document the spectrum of mycobacterial species by culture in children clinically&#xD;
           suspected of having pulmonary tuberculosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Z score for weight and improvement in X ray film</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resolution of symptoms and interferon gamma activity at 2 and 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">403</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Study drug containing zinc alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zinc 20 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study drug Micronutrient without zinc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>micronutrients (vitamin A, thiamine, riboflavin, vitamins B-6 and B-12, folic acid, niacin, vitamins C, E, and D, selenium, and copper) without zinc.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study drug Micronutrient with zinc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>micronutrients in combination with zinc (vitamin A, thiamine, riboflavin, vitamin B-6 and B-12, folic acid, niacin, vitamins C, E, and D, selenium, copper, and 20 mg elemental zinc).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo only</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zinc</intervention_name>
    <description>Zinc 20 mg/day</description>
    <arm_group_label>Study drug containing zinc alone</arm_group_label>
    <other_name>study drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Micronutrient without zinc</intervention_name>
    <description>Multimineral 2 RDA</description>
    <arm_group_label>Study drug Micronutrient without zinc</arm_group_label>
    <other_name>study drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Micronutrient with zinc</intervention_name>
    <description>Multimineral 2 RDA and zinc 20 mg per day</description>
    <arm_group_label>Study drug Micronutrient with zinc</arm_group_label>
    <other_name>study drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>study drug</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  New pulmonary (including pleural) tuberculosis with/without an extrapulmonary lesion&#xD;
             in children age 6 months to 15 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Weight for height &lt; 70 % of NCHS median (reason: zinc as per guidelines is given as&#xD;
             standard point of care to all severely malnourished children)&#xD;
&#xD;
          -  Bilateral pedal oedema&#xD;
&#xD;
          -  Known HIV + ve&#xD;
&#xD;
          -  Place of residence outside Delhi (including physicians discretion)&#xD;
&#xD;
          -  History of previous ATT treatment or INH prophylaxis for more than 48 hours prior to&#xD;
             enrollment&#xD;
&#xD;
          -  Signs of upper airway obstruction, or an arterial oxygen saturation less than 92% in&#xD;
             room air&#xD;
&#xD;
          -  Signs of renal, hepatic, or cvs disease&#xD;
&#xD;
          -  Unable to attend follow up session for reading of Mantoux tests&#xD;
&#xD;
          -  Documented intake of zinc continuously for &gt; 2 weeks in the preceding 4 weeks at&#xD;
             enrollment&#xD;
&#xD;
          -  CNS, osteo-articular, pericardial, renal TB&#xD;
&#xD;
          -  History of contact with a documented case of drug resistant TB&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sushil Kr Kabra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>All India Institute of Medical Sciences, New Delhi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Pediatrics, All India Institute of Medical Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>December 2, 2008</study_first_submitted>
  <study_first_submitted_qc>December 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2008</study_first_posted>
  <last_update_submitted>February 8, 2016</last_update_submitted>
  <last_update_submitted_qc>February 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>All India Institute of Medical Sciences, New Delhi</investigator_affiliation>
    <investigator_full_name>SK Kabra</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>Micronutrient</keyword>
  <keyword>Childhood Tuberculosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zinc</mesh_term>
    <mesh_term>Trace Elements</mesh_term>
    <mesh_term>Micronutrients</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

